Keywords: Novartis, GlaxoSmithKline, TOBI, Gleevec, Altabax, US Justice Department, FDA, Promotion

Novartis to pay over $72 Million to settle False Claims Act allegations related to TOBI; FDA warns of Gleevec and Altabax promo

Article | 05 May 2010

Print This

Swiss drug major Novartis has agreed to pay $72.5 million to resolve civil False Claims Act allegations arising from the marketing ...

Enjoying this article? To continue reading you need to login or subscribe.

Subscribe now
for unlimited access to all articles

Subscriptions are £60 per month, pay as you go.
Find out more details.

Already a subscriber? Click here to log in